Analyzing R&D Budgets: Amgen Inc. vs Zoetis Inc.

A Decade of Innovation: Amgen Inc. vs. Zoetis Inc.

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) budgets are a testament to a company's commitment to innovation. Over the past decade, Amgen Inc. and Zoetis Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amgen consistently allocated a significant portion of its resources to R&D, with expenses peaking in 2021 at nearly 5 billion dollars. This represents a steady increase of approximately 35% from its lowest point in 2017. In contrast, Zoetis Inc., while operating on a smaller scale, has shown a remarkable growth trajectory, with R&D expenses rising by over 50% from 2014 to 2023. This strategic investment underscores Zoetis's commitment to expanding its footprint in the animal health sector. As these two giants continue to innovate, their R&D budgets offer a glimpse into their future directions and priorities.